Bristol Myers Squibbvs.Pfizer
BMY vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Pfizer is about 1.3× larger than Bristol Myers Squibb by market cap; Bristol Myers Squibb trades at the lower P/E (13.0 vs 36.9).
Side by side
| BMY | PFE | |
|---|---|---|
| Market cap | $121B | $160B |
| Price | $59.12 | $28.28 |
| Today | −0.8% | +1.7% |
| Return YTD | +10.5% | +11.7% |
| Return 1Y | +33.8% | +8.3% |
| Since June 26, 2026 | +2.8% | +16.4% |
| P/E | 13.0 | 36.9 |
| P/S | 2.5 | 2.5 |
| P/B | 5.4 | 1.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Bristol Myers SquibbBMY
Opdivo made the company's name in oncology. Immunology and haematology fill out the portfolio, with neuroscience coming through the pipeline.
Full BMY profile →PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →More BMY & PFE comparisons
Other head-to-heads in the Big pharma segment.